BRCA1 185delAG mutation inhibits Akt-dependent, IAP-mediated caspase 3 inactivation in human ovarian surface epithelial cells.

BRCA1 mutations have long been associated with altered apoptosis. We have recently reported that caspase 3 activation is increased in human ovarian surface epithelial (OSE) cells expressing a germline N-terminal BRCA1 185delAG mutation. Here, we report increased caspase 3 activity in 185delAG OSE cells associated with decreased expression of cIAP-1 and X-linked inhibitor of apoptosis (XIAP), and decreased ubiquitination of caspase 3. Overexpression of XIAP restored active caspase 3 ubiquitination and lowered levels of caspase 3 activity. Further, the BRCA1 185delAG mutation was associated with reduced levels of phosphorylated Akt1. Transfection with activated Akt1 led to increased cIAP-1 and XIAP levels similar to that seen in BRCA1 185delAG cell lines. Taken together, these data suggest a direct link between the BRCA1 185delAG mutation and alterations in the caspase-mediated apoptotic pathway.

[1]  E. Asselin,et al.  Akt activity in endometrial cancer cells: regulation of cell survival through cIAP-1. , 2003, International journal of oncology.

[2]  C. Duckett,et al.  The IAP Proteins: Caspase Inhibitors and Beyond , 2000, Science's STKE.

[3]  Michael Fraser,et al.  Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase/Akt pathway. , 2002, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[4]  M. Wood,et al.  Identification of germline 185delAG BRCA1 mutations in non‐Jewish Americans of Spanish ancestry from the San Luis Valley, Colorado , 2003, Cancer.

[5]  Z. Herceg,et al.  Failure of Poly(ADP-Ribose) Polymerase Cleavage by Caspases Leads to Induction of Necrosis and Enhanced Apoptosis , 1999, Molecular and Cellular Biology.

[6]  Alan G. Porter,et al.  Caspase-3 Is Required for DNA Fragmentation and Morphological Changes Associated with Apoptosis* , 1998, The Journal of Biological Chemistry.

[7]  C. Deng,et al.  Roles of BRCA1 and its interacting proteins , 2000, BioEssays : news and reviews in molecular, cellular and developmental biology.

[8]  M. Morgan,et al.  Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. , 1996, The New England journal of medicine.

[9]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[10]  O. Díez,et al.  Identification of the 185delAG BRCA1 mutation in a Spanish Gypsy population , 1998, Human Genetics.

[11]  R. Hartmann-Petersen,et al.  Transferring substrates to the 26S proteasome. , 2003, Trends in biochemical sciences.

[12]  T. Hunter,et al.  The inhibitor of apoptosis, cIAP2, functions as a ubiquitin-protein ligase and promotes in vitro monoubiquitination of caspases 3 and 7. , 2000, The Journal of biological chemistry.

[13]  K. Wilson,et al.  The structures of caspases-1, -3, -7 and -8 reveal the basis for substrate and inhibitor selectivity. , 2000, Chemistry & biology.

[14]  F. Couch,et al.  BRCA1 Facilitates Stress-induced Apoptosis in Breast and Ovarian Cancer Cell Lines* , 2000, The Journal of Biological Chemistry.

[15]  L. Chan,et al.  Proteasome-mediated Degradation of Apolipoprotein B Targets Both Nascent Peptides Cotranslationally Before Translocation and Full-length Apolipoprotein B After Translocation into the Endoplasmic Reticulum* , 1998, The Journal of Biological Chemistry.

[16]  S. Cummings,et al.  Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  D. Green,et al.  Apoptosis: checkpoint at the mitochondrial frontier. , 1999, Mutation research.

[18]  J. Boyd,et al.  Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. , 2000, JAMA.

[19]  V. Cryns,et al.  Proteases to die for. , 1998, Genes & development.

[20]  D. Green,et al.  Caspase-3 Is the Primary Activator of Apoptotic DNA Fragmentation via DNA Fragmentation Factor-45/Inhibitor of Caspase-activated DNase Inactivation* , 1999, The Journal of Biological Chemistry.

[21]  T. Ludwig,et al.  Tumorigenesis in mice carrying a truncating Brca1 mutation. , 2001, Genes & development.

[22]  Robinson Tj.  The seasonal nature of reproductive phenomena in the sheep. II. Variation in fertility following synchronization of oestrus. , 1971 .

[23]  B. Modan,et al.  Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  S. Nicosia,et al.  Akt Phosphorylation and Stabilization of X-linked Inhibitor of Apoptosis Protein (XIAP)* , 2004, Journal of Biological Chemistry.

[25]  P. Kruk,et al.  BRCA1 Zinc RING Finger Domain Disruption Alters Caspase Response in Ovarian Surface Epithelial Cells , 2002, Cancer Cell International.

[26]  P. Kruk,et al.  Simian virus 40-transformed human ovarian surface epithelial cells escape normal growth controls but retain morphogenetic responses to extracellular matrix. , 1992, American journal of obstetrics and gynecology.

[27]  G. Leclerc,et al.  Real-time RT-PCR analysis of mRNA decay: half-life of Beta-actin mRNA in human leukemia CCRF-CEM and Nalm-6 cell lines , 2002, Cancer Cell International.

[28]  J. Bridgham,et al.  Caspase-mediated apoptosis in the vertebrate ovary. , 2002, Reproduction.

[29]  R. Korneluk,et al.  XIAP: Apoptotic brake and promising therapeutic target , 2001, Apoptosis.

[30]  Huan Yang,et al.  Telomerase is regulated by c-Jun NH2-terminal kinase in ovarian surface epithelial cells. , 2002, Cancer research.

[31]  Stephen W. Fesik,et al.  NMR structure and mutagenesis of the inhibitor-of-apoptosis protein XIAP , 1999, Nature.

[32]  Yi Li Yang,et al.  The IAP family: endogenous caspase inhibitors with multiple biological activities , 2000, Cell Research.

[33]  J. Ranstam,et al.  Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  R. Takahashi,et al.  Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[35]  D. Easton,et al.  Risks of cancer in BRCA1-mutation carriers , 1994, The Lancet.